Translational aspects of genetic factors in the prediction of drug response variability: A case study of warfarin pharmacogenomics in a multi-ethnic cohort from Asia

Pharmacogenomics Journal

Volumn 12, Issue 4, 2012, Pages 312-318

  Chan, S L ^a   Suo, C ^a   Lee, S C ^b   Goh, B C ^b   Chia, K S ^a,c,d   Teo, Y Y ^a,c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^c GENOME INSTITUTE OF SINGAPORE   (Singapore)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

drug response variability; pharmacogenomics; translational genetics; warfarin

Indexed keywords

BIOLOGICAL MARKER; WARFARIN;

ASIA; CONTROLLED STUDY; CYP2C9 GENE; CYP4F2 GENE; ETHNICITY; GENE; GENE FREQUENCY; GENE LOCUS; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; OPTIMAL DRUG DOSE; PHARMACOGENOMICS; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; VKORC1 GENE;

ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CYTOCHROME P-450 ENZYME SYSTEM; ETHNIC GROUPS; HUMANS; INDIA; INDIVIDUALIZED MEDICINE; MALAYSIA; MIXED FUNCTION OXYGENASES; PHARMACOGENETICS; POLYMORPHISM, GENETIC; SINGAPORE; WARFARIN;

EID: 84864349523     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2011.7     Document Type: Review

References (33)

1. Kraft P, Wacholder S, Cornelis MC, Hu FB, Hayes RB, Thomas G et al. Beyond odds ratios-communicating disease risk based on genetic profiles. Nat Rev Genet 2009; 10: 264-269.
2. Jakobsdottir J, Gorin MB, Conley YP, Ferrell RE, Weeks DE. Interpretation of genetic association studies: markers with replicated highly significant odds ratios may be poor classifiers. PLoS Genet 2009; 5: e1000337.
3. Kattan MW. Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst 2003; 95: 634-635. (Pubitemid 36603708)
4. Talmud PJ, Hingorani AD, Cooper JA, Marmot MG, Brunner EJ, Kumari M et al. Utility of genetic and non-genetic risk factors in prediction of type 2 diabetes: Whitehall II prospective cohort study. BMJ 2010; 340: b4838.
5. Pharoah PD, Antoniou AC, Easton DF, Ponder BA. Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med 2008; 358: 2796-2803. (Pubitemid 351930854)
6. Nebert DW, Zhang G, Vesell ES. From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions. Drug Metab Rev 2008; 40: 187-224. (Pubitemid 352000946)
7. Daly AK. Genome-wide association studies in pharmacogenomics. Nat Rev Genet 2010; 11: 241-246.
8. Lesko LJ, Zineh I. DNA, drugs and chariots: on a decade of pharmacogenomics at the US FDA. Pharmacogenomics 2010; 11: 507-512.
9. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008; 133(6 Suppl): 160S-198S. (Pubitemid 351892967)
10. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353: 717-719. (Pubitemid 29103806)
11. Wadelius M, Sörlin K, Wallerman O, Karlsson J, Yue QY, Magnusson PK et al. Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics J 2004; 4: 40-48. (Pubitemid 38256604)
12. Wadelius M, Chen LY, Downes K, Ghori J, Hunt S, Eriksson N et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 2005; 5: 262-270. (Pubitemid 41131718)
13. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 2285-2293. (Pubitemid 40740552)
14. Zhao F, Loke C, Rankin SC, Guo JY, Lee HS, Wu TS et al. Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin Pharmacol Ther 2004; 76: 210-219. (Pubitemid 39221795)
15. Lee SC, Ng SS, Oldenburg J, Chong PY, Rost S, Guo JY et al. Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. Clin Pharmacol Ther 2006; 79: 197-205.
16. Tham LS, Goh BC, Nafziger A, Guo JY, Wang LZ, Soong R et al. A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9. Clin Pharmacol Ther 2006; 80: 346-355. (Pubitemid 44479750)
17. Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, Gardina P et al. CYP4F2 genetic variant alters required warfarin dose. Blood 2008; 111: 4106-4112.
18. Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 2009; 5: e1000433.
19. Shikata E, Ieiri I, Ishiguro S, Aono H, Inoue K, Koide T et al. Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood 2004; 103: 2630-2635. (Pubitemid 38393017)
20. Wadelius M, Chen LY, Eriksson N, Bumpstead S, Ghori J, Wadelius C et al. Association of warfarin dose with genes involved in its action and metabolism. Hum Genet 2007; 121: 23-34. (Pubitemid 46421137)
21. Wang TL, Li HL, Tjong WY, Chen QS, Wu GS, Zhu HT et al. Genetic factors contribute to patient-specific warfarin dose for Han Chinese. Clin Chim Acta 2008; 396: 76-79.
22. Yuan HY, Chen JJ, Lee MT, Wung JC, Chen YF, Charng MJ et al. A novel functional VKORC1 promoter polymorphism is associated with interindividual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 2005; 14: 1745-1751. (Pubitemid 41430097)
23. Chen J, Teo YY, Toh DS, Sung C. Interethnic comparisons of important pharmacology genes using SNP databases: potential application to drug regulatory assessments. Pharmacogenomics 2010; 11: 1077-1094.
24. Teo YY, SIM X, Ong RT, Tan AK, Chen J, Tantoso E et al. Singapore Genome Variation Project: a haplotype map of three Southeast Asian populations. Genome Res 2009; 19: 2154-2162.
25. R: A language and environment for statistical computing. Available from: http://www.R-project.org.
26. The International Warfarin Pharmacogenetic Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360: 753-764.
27. Limdi NA, Wadelius M, Cavallari L, Eriksson N, Crawford DC, Lee MT et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 2010; 115: 3827-3834.
28. Scott SA, Khasawneh R, Peter I, Kornreich R, Desnick RJ. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Pharmacogenomics 2010; 11: 781-791.
29. Sagreiya H, Berube C, Wen A, Ramakrishnan R, Mir A, Hamilton A et al. Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9. Pharmacogenet Genomics 2010; 20: 407-413.
30. Goldstein DB, Hirschhorn JN. In genetic control of disease, does 'race' matter? Nat Genet 2004; 36: 1243-1244. (Pubitemid 39577928)
31. Yen-Revollo JL, Auman JT, McLeod HL. Race does not explain genetic heterogeneity in pharmacogenomic pathways. Pharmacogenomics 2008; 9: 1639-1645.
32. Roper N, Storer B, Bona R, Fang M. Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing. J Mol Diagn 2010; 12: 283-291.
33. Shaw PB, Donovan JL, Tran MT, Lemon SC, Burgwinkle P, Gore J. Accuracy assessment of pharmacogenetically predictive warfarin dosing algorithms in patients of an academic medical center anticoagulation clinic. J Thromb Thrombolysis 2010; 30: 220-225.